すべての画像(1)

主要文書

EHU068161

MISSION^® esiRNA

Name: MISSION<SUP>®</SUP> esiRNA
Brand: SIGMA

targeting human CD47

ログイン組織・契約価格を表示する

すべての画像(1)

About This Item

UNSPSCコード:

41105324

NACRES:

NA.51

おすすめの製品

Slide 1 of 10

1 of 10

Sigma-Aldrich

SIC001

MISSION^® siRNA Universal Negative Control #1

SIRNA

MISSION^® siRNA Product Offerings

Roche

SITRAN-RO

X-tremeGENE^™ siRNAトランスフェクション試薬

Sigma-Aldrich

S1452

MISSION^® siRNAトランスフェクション試薬

Sigma-Aldrich

SIC005

MISSION^® siRNA Fluorescent Universal Negative Control #1, Cyanine 5

Sigma-Aldrich

EHU016051

MISSION^® esiRNA

Sigma-Aldrich

MAB8241

抗A型肝炎ウイルス抗体

Sigma-Aldrich

SIC002

MISSION^{^®}siRNA Universal Negative Control #2

SHRNA

MISSION^® shRNA Product Offerings

Sigma-Aldrich

D9542

DAPI

詳細

品質水準

100

製品種目

MISSION^®

形状

lyophilized powder

esiRNA cDNA標的配列

GGCCTCTGGCCTCTAGGTAACCAGTTTAAATTGGTTCAGGGTGATAACTACTTAGCACTGCCCTGGTGATTACCCAGAGATATCTATGAAAACCAGTGGCTTCCATCAAACCTTTGCCAACTCAGGTTCACAGCAGCTTTGGGCAGTTATGGCAGTATGGCATTAGCTGAGAGGTGTCTGCCACTTCTGGGTCAATGGAATAATAAATTAAGTACAGGCAGGAATTTGGTTGGGAGCATCTTGTATGATCTCCGTATGATGTGATATTGATGGAGATAGTGGTCCTCATTCTTGGGGGTTGCCATTCCCACATTCCCCCTTCAACAAACAGTGTAACAGGTCCTTCCCAGATTTAGGGTACTTTTATTGATGGATATGTTTTCCTTTTATTCACATAACCCCTTGAAACCCTG

Ensembl |ヒトアクセッション番号

ENSG00000196776

NCBIアクセッション番号

NM_198793

輸送温度

ambient

保管温度

−20°C

遺伝子情報

human ... CD47(961) , CD47(961)

詳細

MISSION^® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法的情報

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

10 - Combustible liquids

引火点(°F)

Not applicable

引火点(℃)

Not applicable

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA）を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Targeting cluster of differentiation 47 improves the efficacy of anti-cytotoxic T-lymphocyte associated protein 4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma.

Xifu Song et al.

Experimental and therapeutic medicine, 20(4), 3301-3309 (2020-08-29)

Treatment with cluster of differentiation 47 (CD47) monoclonal antibody has exhibited promising antitumor effects in various preclinical cancer models. However, its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In the present study, the CD47 expression level was measured in

CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway.

Xuejian Liu et al.

Oncology research, 27(4), 415-422 (2018-01-13)

Cluster of differentiation 47 (CD47) overexpression is common in various malignancies. This study investigated whether CD47 promotes human glioblastoma invasion and, if so, the underlying mechanisms involved. CD47 expression was found to be stronger in tissues of patients with glioblastoma

CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion.

Natasha M Rogers et al.

Kidney international, 90(2), 334-347 (2016-06-05)

Defects in renal tubular epithelial cell repair contribute to renal ischemia reperfusion injury, cause acute kidney damage, and promote chronic renal disease. The matricellular protein thrombospondin-1 and its receptor CD47 are involved in experimental renal ischemia reperfusion injury, although the

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer.

Hui Zhao et al.

Scientific reports, 6, 29719-29719 (2016-07-15)

CD47 is overexpressed in many human cancers, its level positively correlates with tumor invasion and metastasis. However, it is largely unknown whether CD47 overexpression drives metastasis and how CD47 lead to tumor metastasis in non-small cell lung cancer (NSCLC). In

Immune Effector Functions of Human IgG2 Antibodies against EGFR.

Thies Rösner et al.

Molecular cancer therapeutics, 18(1), 75-88 (2018-10-05)

Three FDA-approved epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab, necitumumab) are clinically available to treat patients with different types of cancers. Interestingly, panitumumab is of human IgG2 isotype, which is often considered to have limited immune effector functions. Unexpectedly

主要文書

MISSION^® esiRNA